title: [Treatment of lupus nephritis].
abstract: Lupus nephritis is a relevant source of morbidity and mortality in patients with systemic lupus erythematosus. The standard therapy of remission induction in severe lupus nephritis is based on the use of monthly intravenous cyclophosphamide. Recent data have established that the maintenance of remission in lupus nephritis can be achieved with azathioprine or mycophenolate mofetil, with less adverse effects than quarterly intravenous cyclophosphamide. In recent years, a number of controlled randomized clinical trials have been published, opening new therapeutic options in the induction of remission in lupus nephritis, such as less aggressive regimens of intravenous cyclophosphamide or mycophenolate mofetil. Further studies are needed for establishing the optimal therapy of lupus nephritis patients.
authors.affiliation: Servicio de Reumatología. Complexo Hospitalario de Pontevedra. Pontevedra. España.
authors.forename: Lucía
authors.initials: L
authors.lastname: Silva Fernández
authors.forename: José Luis
authors.initials: JL
authors.lastname: Andréu Sánchez
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Ginzler